Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 4.5% – Time to Sell?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) dropped 4.5% during trading on Monday . The stock traded as low as $9.33 and last traded at $9.65. Approximately 57,630 shares changed hands during trading, a decline of 18% from the average daily volume of 70,298 shares. The stock had previously closed at $10.11.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen cut Aligos Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Aligos Therapeutics in a report on Friday, September 12th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $50.00.

Aligos Therapeutics Stock Down 4.5%

The stock has a market capitalization of $59.35 million, a PE ratio of -0.49 and a beta of 2.74. The business’s 50-day moving average is $9.30 and its two-hundred day moving average is $9.16.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($3.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.09) by ($0.95). Aligos Therapeutics had a negative return on equity of 39.35% and a negative net margin of 3,267.65%.The firm had revenue of $0.74 million for the quarter, compared to analysts’ expectations of $0.50 million. As a group, analysts anticipate that Aligos Therapeutics, Inc. will post -10.36 EPS for the current year.

Institutional Investors Weigh In On Aligos Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. AlphaQuest LLC acquired a new stake in shares of Aligos Therapeutics in the first quarter valued at approximately $130,000. Adage Capital Partners GP L.L.C. raised its position in Aligos Therapeutics by 43.1% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 465,000 shares of the company’s stock valued at $3,836,000 after purchasing an additional 140,000 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in Aligos Therapeutics in the 1st quarter valued at $3,399,000. Woodline Partners LP acquired a new stake in Aligos Therapeutics during the 1st quarter worth $2,602,000. Finally, Geode Capital Management LLC grew its position in Aligos Therapeutics by 21.3% during the 2nd quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock worth $246,000 after purchasing an additional 5,978 shares during the last quarter. Hedge funds and other institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.